Skip to content
DataLookout
Menu

HEROICNCT07927777

Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Secondary endpoints: details revised at 2 of 12 entries
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Biochemical Recurrence-Free Survival (bRFS)
Timeframe: Through study completion, an average of 3 years

Secondary (10)

Metastasis-Free Survival (MFS)
Pathological Complete Response (pCR)
Minimal Residual Disease (MRD)
Overall Survival (OS)
Time to Castration-Resistant Prostate Cancer (CRPC)
Show 5 moreShow less
Time to First Salvage Therapy (Radiotherapy or systemic)
Testosterone suppression and recovery
PSA kinetics
Quality of Life (QoL)
Safety and tolerability of Relugolix

Arms and interventions

Arm A (Experimental)Experimental

Relugolix orally (loading dose of 360 mg on Day 1, followed by 120 mg once daily) as neoadjuvant therapy for 3 months prior to radical prostatectomy (RP) with extended pelvic lymphadenectomy (ePLND). Subsequently, post-operative adjuvant treatment with Relugolix for 6 months (loading dose 360 mg, followed by 120 mg/day).

Arm B (Control)Active comparator

Immediate undergoing radical prostatectomy (RP) with extended pelvic lymphadenectomy (ePLND), followed by 6 months of post-operative adjuvant treatment with oral Relugolix (loading dose of 360 mg on Day 1, followed by 120 mg once daily).

Drugs: Relugolix-Neoadjuvant treatment, Relugolix-Adjuvant treatment

Sites

12 sites in 1 country